BlackRock, Inc. 13D and 13G filings for Relmada Therapeutics, Inc.:
- Schedule 13D must be filed within ten days after a person or an organization acquires beneficial ownership of more than 5% of a voting class of a company's equity securities.
- Shares have been adjusted for stock splits.
| Reported DateTime | Transaction Date | Type | Company Symbol | Filed By Symbol | Shares Owned % Owned | Shares Vs. Prev Report | View |
| 2023-07-07 4:35 pm Sale | 2023-06-30 | 13G | Relmada Therapeutics, Inc. RLMD | BlackRock Inc. BLK | 605,254 2.000% | -1,257,888 (-67.51%) | Filing |
| 2023-02-01 4:54 pm Purchase | 2022-12-31 | 13G | Relmada Therapeutics, Inc. RLMD | BlackRock Inc. BLK | 1,863,142 6.200% | 477,907 (+34.50%) | Filing |
| 2022-02-03 4:41 pm Sale | 2021-12-31 | 13G | Relmada Therapeutics, Inc. RLMD | BlackRock Inc. BLK | 1,385,235 5.200% | -107,784 (-7.22%) | Filing |
| 2021-02-02 3:13 pm Purchase | 2020-12-31 | 13G | Relmada Therapeutics, Inc. RLMD | BlackRock Inc. BLK | 1,493,019 9.200% | 1,493,019 (New Position) | Filing |